

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

**BMJ** Open

# **BMJ Open**

# The prevalence and risk factors of senile pruritus: a systematic review and meta-analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-051694
Article Type:	Original research
Date Submitted by the Author:	25-Mar-2021
Complete List of Authors:	Chen, Shi; Sichuan University; Sichuan University chen, shi; Sichuan University, Zhou, Faquan; North Sichuan Medical College [Search North Sichuan Medical College]; General Hospital of Western Theater Command Xiong, Yiquan; Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University
Keywords:	Geriatric dermatology < DERMATOLOGY, Dermatological epidemiology < DERMATOLOGY, PERINATOLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

# The prevalence and risk factors of senile pruritus: a systematic review and meta-analysis

Shi Chen<sup>1, 2</sup>\*, Faquan Zhou<sup>3, 4</sup>, Yiquan Xiong<sup>5</sup>

<sup>1</sup> Institute for Disaster Management and Reconstruction, Sichuan University, Chengdu,

Sichuan, China

<sup>2</sup> West China School of Public Health, Sichuan University, Chengdu, Sichuan, China

<sup>3</sup> North Sichuan Medical College, Nan Chong, Sichuan, China

<sup>4</sup> General Surgery Center, General Hospital of Western Theater Command, Chengdu, Sichuan,

China

<sup>5</sup> Chinese Evidence Based Medicine Centre, Sichuan University, Chengdu, Sichuan, China

Short Title: The prevalence and risk factors of senile pruritus: meta-analysis

Corresponding author:

Shi Chen, Institute for Disaster Management and Reconstruction, Sichuan University, No. 2

Section 2, Chuanda Road, Shuangliu District, Chengdu, Sichuan 610227, China. 18408270692

E-mail653645955@qq.com

Number of Tables: 3

Supplementary tables: 1

Number of Figures: 1

Word count: 2071 words

#### Abstract

**Objectives:** To systematically assess the prevalence and risk factors for SP in the elderly ( $\geq 60$  years of age).

**Design:** A meta-analysis were used to pool the prevalence and risk factors for SP estimated from individual studies. Four subgroup analyses were conducted to explore the prevalence for SP in different age, sex, research sites and region.

Setting, participants and measures: Senile pruritus (SP) reduces quality of life in the elderly, yet the worldwide prevalence is unclear. Moreover, the risk factors for SP are controversial. Data from cross-sectional studies, case-control studies and cohort studies that reported the prevalence or the risk factors for SP were collected by searching nine electronic databases up to October 2020, including Web of Science, PubMed, Embase, Cochrane Library, CINAHL, CBM, CNKI, Wanfang and VIP. Two reviewers independently screened studies according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality. Data analysis was performed using Stata 15.1 software.

**Results:** Seventeen studies involving 28,666 participants were included. The overall pooled prevalence of SP was 21.04% (95% confidence intervals (CI): 11.37%-32.72%). In addition, the results showed that smoking, excessive drinking, and monophagism were possible risk factors for SP, with pooled odds ratios (ORs) of 1.26 (95% CI: 1.14-1.40), 25.03 (95% CI:18.28-34.25), and 1.22 (95% CI:1.12-1.33), respectively.

**Conclusions:** The overall prevalence of SP was high. Smoking, excessive drinking and monophagism were possible risk factors for SP.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Keywords: senile pruritus; prevalence; risk factors; systematic review; meta-analysis

Registration: PROSPERO registration number(CRD42019143295).

#### **Strengths and limitations**

• To our knowledge, this study is the first systematic review and meta-analysis providing

comprehensive assessment on the prevalence of senile pruritus in worldwide.

- This study could potentially inform policy and practice to reduce the prevalence of senile pruritus.
- The definitions of SP differed across the included studies.

#### Introduction

The geriatric population (≥ 60 years of age) has been growing steadily worldwide in recent decades. It is estimated that the geriatric population will account for 20% of the world's population by the middle of this century<sup>[1-3]</sup>. Aging results in numerous adverse changes in the structure and function of multiple human organs, including the skin<sup>[4]</sup>. Senile pruritus (SP) is defined as generalized pruritus in patients without primary skin lesions<sup>[5-8]</sup>. Pruritus is the most common skin disorder in the geriatric population<sup>[9]</sup>. It can lead to an unpleasant cutaneous sensation, which provokes the desire to scratch (itchiness) and is accompanied by skin lesions, pain, and infection<sup>[10]</sup>. Furthermore, it can lead to adverse consequences for patients' psychological health and quality of life, including anxiety, depression, disruption of normal sleep patterns, and poor daytime concentration<sup>[10, 11]</sup>. Therefore, investigating the prevalence of SP is essential for informing policymakers, clinicians, and the general population.

#### **BMJ** Open

The prevalence of SP has been reported around the world, ranging from 41% in Thailand<sup>[12]</sup>, 40.6% in America<sup>[13]</sup>, 18.9% in Italy<sup>[14]</sup>, and 14.2% in China<sup>[15]</sup>. However, these studies were limited by sample size and regional differences, and therefore do not represent the prevalence of SP worldwide. Furthermore, several studies conducted surveys on inpatients or outpatients to report the prevalence of SP<sup>[1, 11, 16, 17]</sup>. Inpatients or outpatients do not represent the whole elderly population, making the results less representative of the actual prevalence of SP in the community. For these reasons, the precise prevalence and characteristics of the population are unknown worldwide. Furthermore, the risk factors for SP have been reported extensively, but with controversial conclusions<sup>[18, 19]</sup>. For example, Yang *et al.* indicated that smoking was associated with SP (odds ratio (OR) = 2.23, 95%CI:1.35-17.40) <sup>[18]</sup>. However, Chen et al. reported that smoking was not associated with SP (OR = 1.25, 95%CI: 0.99-1.35)<sup>[19]</sup>. In this study, we conducted a systematic review and meta-analysis to synthesize the prevalence of SP in different ages, sexes, and regions based on the general population and to evaluate the risk factors for SP.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#### **Materials and Methods**

#### **Protocol registration**

This study was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines<sup>[20]</sup> and has been prospectively registered in PROSPERO (registration number: CRD42019143295).

#### Search strategy

#### **BMJ** Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Nine databases were searched in this study, including Web of Science, PubMed, Embase, Cochrane Library, CINAHL, CBM, CNKI, Wanfang, and VIP. The following strategy was used in the searches: (Pruritus OR Itching) AND (Senile OR Aging OR Aged OR Geriatrics) AND (Incidence OR Epidemiology OR Prevalence OR Risk factors). All of the databases were searched from their inception dates to the 24<sup>th</sup> of October 2020. Additional relevant literature was included following a manual search of the included studies reference lists.

#### Inclusion and exclusion criteria

The inclusion criteria were as follows: (1) the study design was either cross-sectional, casecontrol or cohort; (2) participants were over 60 years of age; (3) exact diagnostic criteria for SP were provided; (4) prevalence or risk factors for SP were reported. The exclusion criteria were as follows: the study populations were inpatients and outpatients; the study had incomplete data; republished literature; or studies published in a language other than Chinese or English.

#### **Quality of the studies**

Two independent reviewers assessed the quality of the included studies according to 11 criteria recommended by the American agency for healthcare research and quality (AHRQ). The criteria included assessment of selection bias, performance bias, attrition bias, detection bias, and publication bias. An item would be scored "1" if it was answered "YES", and if it was answered 'NO' or 'UNCLEAR', then the item scored '0' <sup>[21]</sup>, providing a maximum score of 11.

#### **Data extraction**

#### **BMJ** Open

Study selection and data extraction were independently conducted by two reviewers. Any disagreement was resolved by discussion the two reviewers or a third reviewer. The articles were firstly screened by the title and abstract, and then full-text documents were reviewed for inclusion if they reported the prevalence and risk factors for SP. By using a standardized and pilot-tested form, two reviewers independently extracted data from eligible studies, including the title, first author name, publication year, study location, age, sample size, diagnostic criteria, prevalence and risk factors for SP.

#### Data analysis

Double arcsine transformation was used to convert the prevalence of SP. The ORs with their corresponding 95% CIs were selected to assess the effect size of risk factors for SP. Heterogeneity among studies was tested by Cochrane's *Q* and *I*<sup>2</sup> statistics. Heterogeneity was recognized as significant when *I*<sup>2</sup> >50%. A Fixed- effect model (Mantel and Haenszel method) was used if  $I^2 \leq 50\%$ , otherwise a random-effects model (DerSimonian and Laird method) was used<sup>[22]</sup>. Forest plots were constructed for a visual display of the pooled results if necessary. Four subgroup analyses were conducted to explore the prevalence for SP in different age, sex, research sites and region. Sensitivity analysis were assessed by excluding single studies. Publication bias was assessed by using Begg's and Egger's tests<sup>[23]</sup>. Tests of Publication bias and sensitivity analysis were not conducted in the risk factor analysis section due to the limited number of studies included. Statistical analyses were conducted using STATA 15.1 (Stata Corp LP, College Station, TX).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#### **Results**

#### **Study Description**

A total of 8,518 records were identified from the nine databases, of which 647 were duplicates. After screening titles and abstracts, 7,740 records were excluded. Full-text documents of 131 records were screened, 114 studies were excluded, with the remaining 17 studies included in the meta-analysis (Figure 1).

## Characteristics of the included studies

The characteristics of the seventeen studies are summarized in Table 1. Eleven articles were written in Chinese<sup>[18, 19, 24-32]</sup>, and six were written in English <sup>[33-38]</sup>. Thirteen studies were conducted in Asia<sup>[18, 19, 24-32, 34, 36]</sup> and four in Europe <sup>[33, 35, 37, 38]</sup>. Sample sizes ranged from 45<sup>[38]</sup> to 8,252 <sup>[35]</sup>. Four of the seventeen studies reported the risk factors for SP <sup>[18, 19, 25, 32]</sup>.

2
2
4
5
6
7
8
9
10
11
10
12
13
14
15
16
17
18
19
20
21
י∠ רכ
22
23
24
25
26
27
28
29
30
21
21
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
50
51
52
53
54
55
56
57
52
20
27

60

Table 1.	Characteristics	of included	studies.

Authors	Publication	Study area	Diagnostic	Sample size	Prevalence(%)	Risk factors
	Years		criteria			
Dalgard et al. <sup>[33]</sup>	2004	Norway	1	3876	6.91	NA
Li et al. <sup>[24]</sup>	2000	China	NA	534	12.36	NA
Xue et al. <sup>[26]</sup>	2008	China	NA	311	19.29	NA
Ni et al. <sup>[27]</sup>	2012	China	4	426	5.63	NA
Zhang et al. <sup>[28]</sup>	2012	China	NA	1283	9.90	NA
Li et al. <sup>[29]</sup>	2014	China	5	500	33.40	NA
Wu et al. <sup>[30]</sup>	2014	China	5	1286	42.38	NA
Yang et al. <sup>[31]</sup>	2014	China	NA	5000	33.84	NA
Tseng et al. <sup>[34]</sup>	2014	China	NA	313	7.35	NA
Miller et al. <sup>[35]</sup>	2016	Denmark	1	8252	6.31	NA
Kara et al. <sup>[36]</sup>	2017	Turkey	NA	105	19.05	NA
Cowdell et al.[37]	2017	Britain	6	1116	9.32	NA
Dyhre et al. <sup>[38]</sup>	2019	Denmark	7	45	28.89	NA
Ge et al. <sup>[25]</sup>	2006	China	2	1236	66.91	Age; xerosis; Astriction
Yang et al. <sup>[18]</sup>	2009	China	3	3785	61.98	Less water intake; Bathing with soap; Baths
						too much; Smoking; Malignant tumor;
Chen et al. <sup>[19]</sup>	2015	China	4	200	10.50	Bathing with soap; Smoking; Chronic illness;
						Excessive drinking; Monophagism;
			0			Insomnia; Contact with animal
Hou et al. <sup>[32]</sup>	2016	China	(4)	398	18.09	Smoking; Chronic illness; Excessive drinking;
						Monophagism; Insomnia; Contact with
						animal

NA: not available. Diagnostic criteria: ① Self-reported skin complaints scale ; ② participants ≥60 years, an itch lasting more than 2 weeks, Pruritus of whole body or multiple parts, no primary rash, no other pruritic skin disease, no obvious liver and kidney damage, diabetes and mental disease. ③ Dermatology and Venereology; ④ Clinical Dermatology; ⑤ Dermatovenerolog; ⑥ Self-report skin diseases scale[37]; ⑦ Self-report skin diseases scale.

## **Risk of Bias Assessment**

Results of the risk of bias assessment are listed in Table S1. Study quality was found to be moderate in 11 studies and high in the other six studies<sup>[39]</sup>.

## **Prevalence of SP**

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#### **BMJ** Open

Seventeen studies, involving 28,666 participants reported the prevalence of SP, ranging from 5.63% to 66.91%. A random-effects model-based meta-analysis showed that the pooled prevalence of SP was 21.04% (95% *Cl*: 11.37%-32.72%). Subgroup analyses indicated that the pooled prevalence of SP for people aged 60-69, 70-79, 80-89, and  $\geq$ 90 years old were 11.98% (95% *Cl* : 3.91%- 23.62%), 26.79% (95% *Cl* : 8.71%- 50.36%), 51.31% (95% *Cl*: 47.20%- 96.33%) and 57.53% (95% *Cl* : 8.18%-n98.09%), respectively. The pooled prevalence of SP was 8.26% (95% *Cl* : 5.88%-11.00%) in females and 18.65% (95% *Cl* : 0.83%- 51.61%) in males. The pooled prevalence of SP in health examination centers, nursing homes and communities was 43.83% (95% *Cl*: 19.39%- 69.94%), 16.26% (95% *Cl*: (4.55%, 33.29%) and 12.21% (95% *Cl*: 3.46%-25.34%), respectively. The pooled prevalence of SP in Turkey and China was 24.34% (95% *Cl*: 14.03%- 36.38%). The pooled prevalence of SP in Norway, Denmark and Britain was 8.23% (95% *Cl*: 6.36%- 10.35%). The results of subgroup analyses of age, sex, research site and region are shown in Table 2.

Subgroup	Prevalence	95%Cl (%)	Heterogenei	ty
	(%)		l <sup>2</sup> (%)	P value
Age				
60-69	11.98	3.91-23.62	98.1	0.000
70-79	26.79	8.71-50.36	99.7	0.000
80-89	51.31	47.20-96.33	99.6	0.000
≥90	57.53	8.18-98.09	99.0	0.000
Sex				
Females	8.26	5.88-11.00	87.4	0.000
Males	18.65	0.83-51.61	99.9	0.000
Research sites				
Health examination center	43.83	19.39-69.94	99.8	0.000
Nursing homes	16.26	4.55-33.29	93.2	0.000
Community	12.21	3.46-25.34	99.8	0.000
Region				
Turkey, China	24.34%	14.03-36.38%	99.6%	0.000
Norway, Denmark, Britain	8.23%	6.36-10.35%	90.2%	0.000

Table 2. Subgroup analyses by age, sex, research sites and region.

#### **Risk factors**

Four studies, including 5,619 participants, reported the risk factors for SP <sup>[18, 19, 25, 32]</sup>. There were three studies<sup>[18, 19, 32]</sup>, including 4,383 participants, that reported the association of smoking and SP. Meta-analyses showed smoking was associated with SP [pooled OR of 1.26 (95% *Cl* : 1.14-1.40), I<sup>2</sup>=0%]. The results of two studies<sup>[19, 32]</sup>, involving 598 participants, suggested that excessive drinking increased the occurrence of SP [pooled OR of 25.03 (95% Cl:18.28- 34.25), I<sup>2</sup>=0%]. Two studies<sup>[19, 32]</sup> involving 589 participants reported the association of Monophagism and SP [pooled OR of 1.22 (95% *Cl* : 1.12-1.33), I<sup>2</sup>=0%] (Table 3).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### Tab.3 Pooled risk factors of senile pruritus.

No.		0.5		D	Heterogeneity		
	RISK TACLOFS	UK	95%01	Ρ	l <sup>2</sup> (%)	P value	
1	smoking	1.26	1.14 - 1.40	0.000	0%	0.673	
2	excessive drinking	25.03	18.28 - 34.25	0.000	0%	0.980	
3	monophagism	1.22	1.12 -1.33	0.000	0%	0.926	

#### **Sensitivity Analysis**

Sensitivity analysis was performed by excluding a single study and showed that the results of the meta-analysis were stable (18.61%- 22.23%). Sensitivity analysis was not conducted for the risk factor analysis due to the limited number of studies.

### **Publication Bias**

Publication bias was assessed by using Begg's and Egger's tests. Begg's (Z=0.70, P=0.484) and Egger's test (t=0.26, P=0.796) results showed that the possibility of publication bias was less in the overall prevalence pooled analysis. Publication bias was not assessed in the risk factor analysis due to the limited number of studies.

#### Discussion

In this study, 17 studies involving 28,666 participants were included encompassing Norway,

China, Denmark, Turkey, and Britain.

Subgroup analyses found that the difference in the prevalence of SP based on epidemiological factors. Subgroup analyses indicated that a steadily increasing prevalence of SP was associated with increasing age. Xerosis is related to aging and is reported as the most common cause of SP<sup>[40-42]</sup>. One of the skin's most important functions is to retain water. skin surface

#### **BMJ** Open

lipids and sebum on the skin helps retain water<sup>[43]</sup>. As skin ages, there is a decrease in lipids and sebum on the skin, leading to suboptimal moisture retention<sup>[41]</sup>. In addition, immunosenescence occurs with aging and also produces a higher incidence of pruritus<sup>[41]</sup>. Moreover, decreases in androgen, estrogen and glucocorticoid in aged people can contribute to SP<sup>[44, 45]</sup>.

The results of sub-sex and sub-regional analyses found that individuals who were male or living in Turkey and China were associated with a higher prevalence of SP. Sub-research sites analyses found that the highest prevalence of SP was found in health examination centers. The reasons for these results are unclear based on the current scientific knowledge available on SP prevalence. Further studies would be helpful in further exploring these phenomena. In conclusion, the prevalence of SP varies among different populations. However, the reasons underlying the differences in prevalence observed in the current study remain unclear. It is suggested that further studies of the prevalence of SP in different populations be conducted in the future.

Meta-analyses showed that smoking, excessive drinking, and monophagism were possible risk factors for SP. It has been shown that smoking can cause nutrient and oxygen deprivation in cutaneous tissues, decreases collagen and elastin fibers in the dermis, and increases keratinocyte dysplasia<sup>[46]</sup>. These changes reduce skin lipids, sebum, and moisture retention, leading to dryness and pruritus of skin<sup>[47, 48]</sup>. Therefore, smoking is a potential risk factor for SP. The present study also identified drinking alcohol as a potential risk factor for SP. Studies have demonstrated that alcohol consumption could reduce the concentration of carotenoids

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### **BMJ** Open

in the skin<sup>[49]</sup>. Carotenoids can neutralize free radicals, delay premature skin aging and skin diseases caused by free radicals<sup>[49-51]</sup>. It could be proposed that alcohol consumption may lead to skin diseases by affecting the concentration of carotenoids. The human body cannot synthesize carotenoids in sufficient amounts without relying on a nutrient rich diet including fruit and vegetables. Therefore, monophagism could contribute to reducing the concentration of carotenoids and it could be considered a risk factors for skin diseases.

Although the present study indicated smoking, excessive drinking and monophagism were associated with an increased risk of SP, all the studies included in the meta-analysis were cross-sectional. Consequently, It is not possible to infer on the causality between exposure and outcomes. Further studies are needed to confirm these findings. In addition to the three risk factors identified through the meta-analyses, the included studies also showed that the risk factors for SP also include age, xerosis, astriction, less water intake, bathing with soap, bathing too frequently, malignant tumor, chronic illness, excessive drinking, insomnia, and contact with animals.

To the best of our knowledge, this study is the first to provide a systematic review of SP prevalence and risk factors. However, several limitations of this study should be noted. First, The epidemiological data on SP was only from Norway, China, Denmark, Turkey, Britain, and Denmark, which cannot be generalized to the worldwide population. Second, the methods of identifying SP varied among the included studies, and no diagnostic assessment was performed in some studies, making it difficult to analyze the prevalence of SP using a gold

 standard method. Considering these limitations, further studies will be needed to better understand the prevalence and risk factors of SP worldwide.

#### Conclusion

In conclusion, this study found the prevalence of SP was 21.04%. Individuals who were older,

male, or living in Turkey and China were associated with a higher prevalence of SP.

Additionally, among health examination centers, nursing homes and communities, the highest

detection rate of SP was found in the health examination centers. Smoking, excessive drinking

and monophagism were possible individual risk factors for SP.

#### References

- Valdes RR, Mollanazar NK, González MJ, et al. Itch Prevalence and Characteristics in a Hispanic Geriatric Population: A Comprehensive Study Using a Standardized Itch Questionnaire. Acta Derm Venereol. 2015;95(4):417-421. doi:10.2340/00015555-1968.
- Hosseinpoor AR, Bergen N, Chatterji S. Socio-demographic determinants of caregiving in older adults of low- and middle-income countries. Age Ageing. 2013;42(3):330-338. doi:10.1093/ageing/afs196.
- Darjani A, Mohtasham AZ, Mohammad AK, et al. Skin Disorders among Elder Patients in a Referral Center in Northern Iran. Dermatol Res Pract. 2013;2013:193205. doi:10.1155/2013/193205.
- 4. Reszke R, Pełka D, Walasek A, et al. Skin disorders in elderly subjects. Int J Dermatol. 2015;54(9):332-338. doi: 10.1111/ijd.12832.
- Zhang Q, Wang HZ, Gao J, et al. Effect of Traditional Chinese Medicine desire adjustment therapy on sleep quality in patients with senile skin pruritus. Chin J Nurs. 2017;52(2):161-165. doi:10.3761/j.issn.0254-1769.2017.02.007.
- Ständer S, Weisshaar E, Mettang T, et al. Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch. Acta Derm Venereol. 2007;87(4):291-4. doi:10.2340/00015555-0305.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2	
4	
5	
6	
/ 8	
9	
10	
11	
12	
14	
15	
16 17	
18	
19	
20	
21	
23	
24	
25	
20	
28	
29	
30	
32	
33	
34	
35 36	
37	
38	
39 40	
40	
42	
43	
44 45	
46	
47	
48	
50	
51	
52	
53 54	
55	
56	
57	
58 59	
60	

- Clerc CJ, Misery L. Venereologica, A Literature Review of Senile Pruritus: From Diagnosis to Treatment. Acta Derm Venereol. 2017;97(4):433-440.
   doi:10.2340/00015555-2574.
- 8. Reich A, Ständer S, Szepietowski JC. Pruritus in the elderly. Clin Dermatol. Jan-Feb 2011;29(1):15-23. doi: 10.1016/j.clindermatol.2010.07.002.
- 9. Cohen KR, Frank J, Salbu RL, et al. Pruritus in the elderly: Clinical approaches to the improvement of quality of life. P&T. 2012;37(4): 227-239.
- 10. Zhang Q,Gao J,Shi LH, et al. Effect of Traditional Chinese Medicine desire adjustment therapy on symptom and the quality of life in patients with senile skin pruritu. Chin J Geront. 2016. 36(19): 4897-4899. doi:10.3969/j.issn.1005-9202.2016.19.105.
- Teoh YL, Teo RY, Yeo B, et al. Elderly Hospitalised Patients-The Impact of Itch and its Prevalence. Ann Acad Med Singapore. 2016;45(4):134-137.
   PMID:27292003.
- 12. Thaipisuttikul Y. Pruritic Skin Diseases in the Elderly. J Dermatol. 1998 ;25(3):153-157. doi:10.1111/j.1346-8138.1998.tb02371.x.
- 13. Caretti KL, Mehregan DR, Mehregan DA. A survey of self-reported skin disease in the elderly African-American population. Int J Dermatol. 2015;54(9):1034-8. doi:10.1111/ijd.12520.
- Rubegni P, Poggiali S, Nami N, et al. Skin diseases in geriatric patients: Our experience from a public skin outpatient clinic in Siena. 2012;147(6):631-636.
   PMID:23149709
- Liao YH, Chen KH, Tseng MP, et al. Pattern of Skin Diseases in a Geriatric Patient Group in Taiwan: A 7-Year Survey from the Outpatient Clinic of a University Medical Center. Dermat. 2001;203(4):308-313. doi:10.1159/000051778.
- 16. Reszke R, Pełka D, Walasek A, et al. Skin disorders in elderly subjects. Int J Dermatol. 2015;54(9):332-338. doi:10.1111/ijd.12832.
- 17. Reszke R, Białynicki-Birula R, Lindner K, et al. Itch in Elderly People: A Cross-sectional Study. Acta Derm Venereol. 2019 ;99(11):1016-1021. doi:10.2340/00015555-3271.

18.	Yang J, Zhao H, Zhou Y, et al. A case-control study on risk of 410 male senile pruritus. Mod Prevent Med, 2009;36(10):1820-1822.
19.	Chen ZH, Mo HX, Xian JF, et al. The study on the morbidity of common senile dermatosis in Junjing community in Guangzhou city. J Jinan Univ. 2015;36(1): 73-76. doi:10.11778/j.jdxb.2015.01.013.
20.	Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Syst Rev. 2015;4(1):1.doi: 10.1186/2046-4053-4-1.
21.	Zeng XT,Liu H,Chen X,et al. Meta analysis series 4: quality assessment tools for observational studies.Chin J Evid Based Cardiovasc Med. 2012;4(04):297-299.
22.	Barili F, Parolari A, Kappetein PA, et al. Statistical Primer: heterogeneity, random- or fixed-effects model analyses? Interact Cardiovasc Thorac Surg. 2018;27(3):317-321.doi: 10.1093/icvts/ivy163.
23.	Herrmann D, Sinnet,P, Holmes J, et al. Statistical controversies in clinical research: publication bias evaluations are not routinely conducted in clinical oncology systematic reviews. Ann Oncol. 2017 May 1;28(5):931-937. doi: 10.1093/annonc/mdw691.
24.	Li XS, He BX, Yang XQ. Investigation of dermatosis in cadres above division level in Changchun. Shenyang Budui Yiyao. 2000; 13(1):39.
25.	Ge NL, Xie ZH, Zhang CL, et al. A case-control study on risk of 122 simple senile pruritus. Chin J Epidemiol. 2006;27(7):627-629.
26.	Xue SQ. Survey on Elderly Skin Disorders of Workers in Taigang Factory. Chin J Dermatovenereol, 2008;22(7):409-410.
27.	Ni HL,Ke XY,Qian MQ, et al. Analysis of Prevalence of Elderly Itch Skin Disease in Two Pension Institutions in Shanghai. Chin J Dermato Venerol Integ Trad W Med, 2012;11(3): 157-158.
28.	Zhang L. The Dermatopathic Study Of Middle—age and elderly Cadres In TaiYuan. Shanxi Medical University. Taiyuan, Shanxi, China, 2012.
29.	Li L,Wang T,Liu XZ. Analysis of risk factors and health guidance for senile pruritus. J Mili Surg in Southwest Chin. 2014;(5):591-592. doi:10.3969/j.issn.1672-7193.2014.05.050.

30.	Wu N,Zhang DL. Investigation and etiological analysis of senile pruritus. Chin J Convalescent Med. 2014;23(04):368-369. doi:10.13517/j.cnki.ccm.2014.04.051.
31.	Yang J, Dou N, Ma SH, et al. Influencing factors of senile pruritus in Tangshan city. Chin J Geront. 2014;34(18):5205-5207. doi:10.3969/j.issn.1005- 9202.2014.18.087.
32.	Hou XF, Zhang LJ. Investigation and analysis of 196 influencing factors of elderly dermatosis. Shaanxi Med. 2016;45(11):1559-1560. doi:10,11778/j.jdxb.2015.01.013.
33.	Dalgard F, Svensson A, Holm J, et al. Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study. Br J Dermatol. 2004 ;151(2):452-457. doi:10.1111/j.1365- 2133.2004.06058.x.
34.	Tseng HW, Lam HC, Ger LP, et al. A survey of dermatological diseases among older male adults of a Veterans Home in Southern Taiwan. Aging Clin Exp Res. 2015;27(2):227-33. doi:10.1007/s40520-014-0260-9.
35.	Miller IM, Zarchi K, Ellervik C, et al. Self-reported skin morbidity in Denmark: A population-based cross-sectional study. Eur J Dermatol. 2016;26(3):281-6. doi:10.1684/ejd.2016.2766.
36.	Kara PA, Alatas ET, Doğan G, et al. Prevalence of Skin Diseases among Elderly Residing in Nursing Homes in Mugla. TURK J GERIATR. 2017;20(1):23-29.
37.	Cowdell F, Dyson J, Long J, et al. Self-reported skin concerns: An epidemiological study of community-dwelling older people. Int J Older People Nurs. 2018;13(3):12195. doi: 10.1111/opn.
38.	Dyhre PN, Gazerani P. Presence and characteristics of senile pruritus among Danish elderly living in nursing homes. Future Sci OA, 2019;5(6):Fso399. doi:10.2144/fsoa-2019-0036.
39.	Xiong F, Lai YQ, Tu JX, et al. Epidemiological characteristics of sleep disorders in the Chinese elderly: a meta-analysis. Chin J Evid-Based Med. 2020;19(4):398- 403. doi:10.7507/1672-2531.201808151.

40.	Valdes RR, Stull C, Yosipovitch G. Chronic Pruritus in the Elderly: Pathophysiology, Diagnosis and Management. Drugs Aging. 2015;32(3):201-15. doi:10.1007/s40266-015-0246-0.
41.	Patel T, Yosipovitch G. The Management of Chronic Pruritus in the Elderly. Skin Therapy Lett. 2010;15(8):5-9. 2010. PMID: 20844849.
42.	Paul C, Maumus RS, Mazereeuw HJ, et al. Prevalence and Risk Factors for Xerosis in the Elderly: A Cross-Sectional Epidemiological Study in Primary Care. Dermatol. 2011;223(3):260-5. doi: 10.1159/000334631.
43.	Berger TG, Shive M, Harper GM. Pruritus in the older patient: a clinical review. JAMA. 2013;310(22):2443-50. doi:10.1001/jama.2013.282023.
44.	Zhang ZJ, Zhu J, Me H, et al. Advances in the pathogenesis of senile pruritus. Chin J Geront. 2018,38(18),4598-4600. doi:10.3969/j.issn.1005- 9202.2018.18.087.
45.	Liu YS. Endocrine system characteristics and diseases of the elderly. Chin J Geriatr. 2005;24(8):637-639.
46.	Leow YH, Maibach HI. Cigarette smoking, cutaneous vasculature, and tissue oxygen. Clin Dermatol. 1998 Sep-Oct;16(5):579-84. doi: 10.1016/s0738- 081x(98)00042-x.
47.	Farage MA, Miller KW, Elsner P, et al. Intrinsic and extrinsic factors in skin ageing: a review. Int J Cosmet Sci. 2008 Apr;30(2):87-95. doi: 10.1111/j.1468-2494.2007.00415.x.
48.	Friedman O. Changes associated with the aging face. Facial Plast Surg Clin North Am. 2005 Aug;13(3):371-80. doi: 10.1016/j.fsc.2005.04.004.
49.	Lademann J, Meinke MC, Sterry W, et al. Carotenoids in human skin. Exp Dermatol. 2011 May;20(5):377-82. doi: 10.1111/j.1600-0625.2010.01189.x. Epub 2011 Mar 1.
50	Berson DS. Natural antioxidants. J Drugs Dermatol. 2008 Jul;7(7 Suppl):s7-12.
51.	Stahl W, Sies H. Bioactivity and protective effects of natural carotenoids. Biochim Biophys Acta. 2005 May 30;1740(2):101-7. doi:10.1016/j.bbadis.2004.12.006. Epub 2004 Dec 28.

- 50 Berson DS. Natural antioxidants. J Drugs Dermatol. 2008 Jul;7(7 Suppl):s7-12.
- 51. Stahl W, Sies H. Bioactivity and protective effects of natural carotenoids.
  Biochim Biophys Acta. 2005 May 30;1740(2):101-7.
  doi:10.1016/j.bbadis.2004.12.006. Epub 2004 Dec 28.

#### Footnotes

#### **Author Statement**

**Contributions:** Shi Chen and Fa-quan Zhou contributed equally to this study. Shi Chen conceived and participated in the design of this review. Shi Chen and Fa-quan Zhou performed the literature searches, study selection, data extraction, and assessed the risk of bias. Shi Chen and Fa-quan Zhou drafted the manuscript. Yi-quan Xiong helped in performing the analysis with constructive discussions. Shi Chen revised the final version. All authors read and approved the final manuscript.

#### Funding: none

**Conflict of interests:** All of the authors declare that they have no financial or commercial conflicts of interest.

Ethics approval: This article does not contain any studies with human participants or

animals performed by any of the authors.

Patient consent for publication: Not required.

Patient and public involvement: Patients and/or the public were not involved in the

design, conduct, reporting or dissemination plans of this research.

Data availability statement: All data relevant to the study are included in the article or

uploaded as supplementary information.

Page 21 of 23

## Figure





Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#### 

## Supplementary table caption

Tab.S1 Risk of bias assessment for studies included.

Study	1	2	3	4	5	6	7	8	9	10	11	Total
												score
Li et al. <sup>[24]</sup>	Y	Ν	Y	Y	U	Y	Ν	Y	Ν	Ν	Ν	5
Dalgard et al. <sup>[33]</sup>	Y	Y	Y	Y	U	Y	Y	Y	Y	Y	Ν	8
Ge et al. <sup>[25]</sup>	Y	Y	Y	Y	U	Y	Y	Y	Ν	Y	Ν	8
Xue et al. [26]	Y	N	Ν	Y	U	Y	Y	Ν	N	Y	Ν	5
Yang et al. <sup>[18]</sup>	Y	Y	Y	Y	U	Y	Y	Y	N	Y	N	8
Ni et al. <sup>[27]</sup>	Y	Y	Y	Y	U	Y	Ν	Ν	N	Y	Ν	6
Zhang et al. <sup>[28]</sup>	Y	Y	Y	Y	U	Y	Ν	Ν	N	Y	Ν	6
Li et al. <sup>[29]</sup>	Y	Y	Ν	Y	U	Y	Ν	Ν	N	Y	Ν	5
Wu et al. <sup>[30]</sup>	Y	Y	Y	Y	U	Y	Ν	Ν	N	Y	Ν	6
Yang et al. <sup>[31]</sup>	Y	Y	Y	Y	U	Y	Y	Y	N	Y	Ν	8
Tseng et al. <sup>[34]</sup>	Y	N	Y	Y	U	Y	Y	Y	N	Y	Y	7
Chen et al. <sup>[19]</sup>	Y	Y	Y	Y	U	Y	Y	Ν	N	Y	N	7
Hou et al. <sup>[32]</sup>	Y	Y	Y	Y	U	Y	Y	Ν	N	Y	N	7
Miller et al. <sup>[35]</sup>	Y	Y	Y	Y	υ	Y	Y	Y	N	Y	Ν	8
Kara et al. <sup>[36]</sup>	Y	Y	Y	Y	U	Y	Y	Ν	N	Y	N	7
Cowdell et al. <sup>[37]</sup>	Y	Y	Y	Y	U	Y	Y	Ν	Ν	Y	Ν	7
Dyhre et al. <sup>[38]</sup>	Y	Y	Y	Y	U	Y	γ	Ν	Y	Y	N	8

Y=YES; N= NO; U=Unclear; Score of Item (point): 1. Define the source of information (survey, record review); 2. List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications; 3. Indicate time period used for identifying patients; 4. Indicate whether or not subjects were consecutive if not population-based; 5. Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants; 6. Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements); 7. Explain any patient exclusions from analysis; 8. Describe how confounding was assessed and/or controlled; 9. If applicable, explain how missing data were handled in the analysis; 10. Summarize patient response rates and completeness of data collection; 11. Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained.

Pa	age 23 of 23		BMJ Open G BMJ Open by jo	
1 2 3	PRISMA 20	009	Checklist	
4 5 6	Section/topic	#	Checklist item	Reported on page #
7	TITLE		g fo	
8 9	Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
10	ABSTRACT		s reiry	
11 12 13 14	Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data solt as study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitation and implications of key findings; systematic review registration number.	1-2
15	INTRODUCTION			
16	Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
18	Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, herventions, comparisons, outcomes, and study design (PICOS).	3-4
20	METHODS		9. <del>5</del>	
22 23	Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	4
24 25 26	Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics	5
27 28	Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
29 30 31	Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
32 33	Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic www, and, if applicable, included in the meta-analysis).	6
34 35 36	Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in diplicate) and any processes for obtaining and confirming data from investigators.	6
37	Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
39 40	Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
42	Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
43 44 45	Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	6



## **PRISMA 2009 Checklist**

		BMJ Open	Page 24 of 2			
1 PRISMA 20	009	Checklist				
3		Page 1 of 2				
5 6 Section/topic	#	Checklist item	Reported on page #			
<ul> <li>Risk of bias across studies</li> <li>9</li> </ul>	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6			
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-registric ion), if done, indicating which were pre-specified.	6			
13 RESULTS		d to				
14 Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with a flow diagram.	7			
17 17 Study characteristics 18	18	For each study, present characteristics for which data were extracted (e.g., study size, Protections, follow-up period) and provide the citations.	7-8			
19 Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessme	8			
20 21 Results of individual studies 22	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple sum and data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot	9-11			
23 Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measured of consistency.	9-11			
24 25 Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	11			
<sup>26</sup> Additional analysis	Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta grassion [see Item 16]). 11					
28 DISCUSSION	1	<u> </u>				
29 30 31	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	11-13			
32 Limitations 33	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13-14			
<sup>34</sup> Conclusions 35	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14			
	_1	ge				
37 38 Funding 39	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19			
40 41 <i>From:</i> Moher D, Liberati A, Tetzlaf 42 doi:10.1371/journal.pmed1000097 43 44	ff J, Altm	han DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The BRISMA Statement. PLoS Med For more information, visit: www.prisma-statement.org. Page 2 of 2 For peer review only - http://bmiopen.bmi.com/site/about/guidelines.xhtml	6(6): e1000097.			
45		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml				

**BMJ** Open

# **BMJ Open**

# The prevalence and risk factors of senile pruritus: a systematic review and meta-analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-051694.R1
Article Type:	Original research
Date Submitted by the Author:	07-Jan-2022
Complete List of Authors:	chen, shi; Sichuan University, Zhou, Faquan; North Sichuan Medical College [Search North Sichuan Medical College]; General Hospital of Western Theater Command Xiong, Yiquan; Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University
<b>Primary Subject Heading</b> :	Dermatology
Secondary Subject Heading:	Epidemiology, Geriatric medicine, Public health
Keywords:	Geriatric dermatology < DERMATOLOGY, Dermatological epidemiology < DERMATOLOGY, PERINATOLOGY

## SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

2	
3	
4	
5	
5	
0	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
10	
20	
∠∪ ว1	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
37	
32 33	
22	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
16	
-+0 ∕17	
4/	
4ð	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	
72	
00	

1	The prevalence and risk factors of senile pruritus: a systematic
2	review and meta-analysis
3	Shi Chen <sup>1, 2</sup> *, Faquan Zhou <sup>3, 4</sup> , Yiquan Xiong <sup>5</sup>
4	<sup>1</sup> Institute for Disaster Management and Reconstruction, Sichuan University, Chengdu,
5	Sichuan, China
6	<sup>2</sup> West China School of Public Health, Sichuan University, Chengdu, Sichuan, China
7	<sup>3</sup> North Sichuan Medical College, Nan Chong, Sichuan, China
8	<sup>4</sup> General Surgery Center, General Hospital of Western Theater Command, Chengdu, Sichuan,
9	China
10	<sup>5</sup> Chinese Evidence Based Medicine Centre, Sichuan University, Chengdu, Sichuan, China
11	Short Title: The prevalence and risk factors of senile pruritus: meta-analysis
12	Corresponding author:
13	Shi Chen, Institute for Disaster Management and Reconstruction, Sichuan University, No. 2
14	Section 2, Chuanda Road, Shuangliu District, Chengdu, Sichuan 610227, China. 18408270692
15	E-mail653645955@qq.com
16	Number of Tables: 3
17	Supplementary tables: 2
18	Number of Figures: 1
19	Word count: 3173 words

**BMJ** Open

1	Abstract
2	Objectives: To systematically assess the prevalence and risk factors for Senile pruritus (SP)
3	in the elderly ( $\geq$ 60 years of age).
4	Design: A meta-analysis were used to pool the prevalence and risk factors for SP estimated
5	from individual studies. Four subgroup analyses were conducted to explore the prevalence
6	for SP in different age, sex, research sites and region.
7	Setting, participants and measures: SP reduces quality of life in the elderly, yet the worldwide
8	prevalence is unclear. Moreover, the risk factors for SP are controversial. Data from cross-
9	sectional studies, case-control studies, longitudinal studies and cohort studies that reported
10	the prevalence or the risk factors for SP were collected by searching nine electronic databases
11	up to October 2020, including Web of Science, PubMed, Embase, Cochrane Library, CINAHL,
12	CBM, CNKI, Wanfang and VIP. Two reviewers independently screened studies according to the
13	inclusion and exclusion criteria, extracted data, and assessed methodological quality. Data
14	analysis was performed using Stata 15.1 software.
15	Results: Seventeen studies involving 28,666 participants were included. The overall pooled
16	prevalence of SP was 21.04% (95% confidence intervals [CI]: 11.37%-32.72%). In addition, the
17	results showed that smoking, excessive drinking, and monophagism were possible risk factors
18	for SP, with pooled odds ratios (ORs) of 1.26 (95% CI: 1.14-1.40), 25.03 (95% CI:18.28-34.25),
19	and 1.22 (95% CI:1.12-1.33), respectively.
20	Conclusions: The overall prevalence of SP was high. Smoking, excessive drinking and
21	monophagism were possible risk factors for SP.

**BMJ** Open

2		
3	-	
4	1	<b>Keywords:</b> senile pruritus; prevalence; risk factors; systematic review; meta-analysis
6		
7	2	Registration: PROSPERO registration number(CRD42019143295).
8		
9	9	Strongthe and limitations
10	3	Strengths and minitations
11		
12	4	<ul> <li>To our knowledge, this study is the first systematic review and meta-analysis providing</li> </ul>
13 14		
14	5	comprehensive assessment on the prevalence of senile pruritus in worldwide
16	0	comprehensive assessment on the prevalence of senice prantas in worldwide.
17	C	
18	6	The risk factors of senile pruritus are evaluated.
19		
20	7	This systematic review and meta-analysis, covering 5 different countries, was composed
21		
22	8	of 17 studies, with 28,666 participants were included
24	0	of 17 studies, with 28,000 participants were included.
25	0	
26	9	<ul> <li>The definitions of SP differed across the included studies.</li> </ul>
27		
28	10	
29 30		
31	11	
32	11	
33		
34	12	
35		
30 37	13	
38		
39	14	
40	14	
41		
42	15	
45 44		
45	16	
46		
47	17	
48	11	
49		
5U 51	18	
52		
53	19	
54		
55	20	
56	20	
5/ 58		
59	21	
60		

2
3
4
5
6
6
7
8
9
10
11
12
12
13
14
15
16
17
18
19
20
∠∪ ⊃1
21
22
23
24
25
26
27
27
28
29
30
31
32
33
34
25
22
36
37
38
39
40
41
12
т <u>∠</u> 42
45
44
45
46
47
48
49
50
50
21
52
53
54
55
56
57
57
58
59
60

1 Introduction
----------------

Z	The geriatric population ( $\geq$ 60 years of age) has been growing steadily worldwide in recent
3	decades. It is estimated that the geriatric population will account for 20% of the world's
4	population by the middle of this century $^{[1-3]}$ . Aging results in numerous adverse changes in the
5	structure and function of multiple human organs, including the skin <sup>[4]</sup> . Senile pruritus (SP) is
6	defined as generalized pruritus in patients without primary skin lesions <sup>[5-8]</sup> . Pruritus is the most
7	common skin disorder in the geriatric population <sup>[9]</sup> . It can lead to an unpleasant cutaneous
8	sensation, which provokes the desire to scratch (itchiness) and is accompanied by skin lesions,
9	pain, and infection <sup>[10]</sup> . Furthermore, it can lead to adverse consequences for patients'
10	psychological health and quality of life, including anxiety, depression, disruption of normal
11	sleep patterns, and poor daytime concentration <sup>[10, 11]</sup> . Therefore, investigating the prevalence
12	of SP is essential for informing policymakers, clinicians, and the general population.
12 13	of SP is essential for informing policymakers, clinicians, and the general population. The prevalence of SP has been reported around the world, ranging from 41% in Thailand <sup>[12]</sup> ,
12 13 14	of SP is essential for informing policymakers, clinicians, and the general population. The prevalence of SP has been reported around the world, ranging from 41% in Thailand <sup>[12]</sup> , 40.6% in America <sup>[13]</sup> , 18.9% in Italy <sup>[14]</sup> , and 14.2% in China <sup>[15]</sup> . However, these studies were
12 13 14 15	of SP is essential for informing policymakers, clinicians, and the general population. The prevalence of SP has been reported around the world, ranging from 41% in Thailand <sup>[12]</sup> , 40.6% in America <sup>[13]</sup> , 18.9% in Italy <sup>[14]</sup> , and 14.2% in China <sup>[15]</sup> . However, these studies were limited by sample size and regional differences, and therefore do not represent the
12 13 14 15 16	of SP is essential for informing policymakers, clinicians, and the general population. The prevalence of SP has been reported around the world, ranging from 41% in Thailand <sup>[12]</sup> , 40.6% in America <sup>[13]</sup> , 18.9% in Italy <sup>[14]</sup> , and 14.2% in China <sup>[15]</sup> . However, these studies were limited by sample size and regional differences, and therefore do not represent the prevalence of SP worldwide. Furthermore, several studies conducted surveys on inpatients or
12 13 14 15 16 17	of SP is essential for informing policymakers, clinicians, and the general population. The prevalence of SP has been reported around the world, ranging from 41% in Thailand <sup>[12]</sup> , 40.6% in America <sup>[13]</sup> , 18.9% in Italy <sup>[14]</sup> , and 14.2% in China <sup>[15]</sup> . However, these studies were limited by sample size and regional differences, and therefore do not represent the prevalence of SP worldwide. Furthermore, several studies conducted surveys on inpatients or outpatients to report the prevalence of SP <sup>[1, 11, 16, 17]</sup> . Inpatients or outpatients do not represent
12 13 14 15 16 17 18	of SP is essential for informing policymakers, clinicians, and the general population. The prevalence of SP has been reported around the world, ranging from 41% in Thailand <sup>[12]</sup> , 40.6% in America <sup>[13]</sup> , 18.9% in Italy <sup>[14]</sup> , and 14.2% in China <sup>[15]</sup> . However, these studies were limited by sample size and regional differences, and therefore do not represent the prevalence of SP worldwide. Furthermore, several studies conducted surveys on inpatients or outpatients to report the prevalence of SP <sup>[1, 11, 16, 17]</sup> . Inpatients or outpatients do not represent the whole elderly population, making the results less representative of the actual prevalence
12 13 14 15 16 17 18 19	of SP is essential for informing policymakers, clinicians, and the general population. The prevalence of SP has been reported around the world, ranging from 41% in Thailand <sup>[12]</sup> , 40.6% in America <sup>[13]</sup> , 18.9% in Italy <sup>[14]</sup> , and 14.2% in China <sup>[15]</sup> . However, these studies were limited by sample size and regional differences, and therefore do not represent the prevalence of SP worldwide. Furthermore, several studies conducted surveys on inpatients or outpatients to report the prevalence of SP <sup>[1, 11, 16, 17]</sup> . Inpatients or outpatients do not represent the whole elderly population, making the results less representative of the actual prevalence of SP in the community. For these reasons, the precise prevalence and characteristics of the
12 13 14 15 16 17 18 19 20	of SP is essential for informing policymakers, clinicians, and the general population. The prevalence of SP has been reported around the world, ranging from 41% in Thailand <sup>[12]</sup> , 40.6% in America <sup>[13]</sup> , 18.9% in Italy <sup>[14]</sup> , and 14.2% in China <sup>[15]</sup> . However, these studies were limited by sample size and regional differences, and therefore do not represent the prevalence of SP worldwide. Furthermore, several studies conducted surveys on inpatients or outpatients to report the prevalence of SP <sup>[1, 11, 16, 17]</sup> . Inpatients or outpatients do not represent the whole elderly population, making the results less representative of the actual prevalence of SP in the community. For these reasons, the precise prevalence and characteristics of the population are unknown worldwide. Furthermore, the risk factors for SP have been reported
12 13 14 15 16 17 18 19 20	of SP is essential for informing policymakers, clinicians, and the general population. The prevalence of SP has been reported around the world, ranging from 41% in Thailand <sup>[12]</sup> , 40.6% in America <sup>[13]</sup> , 18.9% in Italy <sup>[14]</sup> , and 14.2% in China <sup>[15]</sup> . However, these studies were limited by sample size and regional differences, and therefore do not represent the prevalence of SP worldwide. Furthermore, several studies conducted surveys on inpatients or outpatients to report the prevalence of SP <sup>[1, 11, 16, 17]</sup> . Inpatients or outpatients do not represent the whole elderly population, making the results less representative of the actual prevalence of SP in the community. For these reasons, the precise prevalence and characteristics of the population are unknown worldwide. Furthermore, the risk factors for SP have been reported
12 13 14 15 16 17 18 19 20 21	of SP is essential for informing policymakers, clinicians, and the general population. The prevalence of SP has been reported around the world, ranging from 41% in Thailand <sup>[12]</sup> , 40.6% in America <sup>[13]</sup> , 18.9% in Italy <sup>[14]</sup> , and 14.2% in China <sup>[15]</sup> . However, these studies were limited by sample size and regional differences, and therefore do not represent the prevalence of SP worldwide. Furthermore, several studies conducted surveys on inpatients or outpatients to report the prevalence of SP <sup>[1, 11, 16, 17]</sup> . Inpatients or outpatients do not represent the whole elderly population, making the results less representative of the actual prevalence of SP in the community. For these reasons, the precise prevalence and characteristics of the population are unknown worldwide. Furthermore, the risk factors for SP have been reported extensively, but with controversial conclusions <sup>[18, 19]</sup> . For example, Yang <i>et al.</i> indicated that

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

**BMJ** Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

	1	smoking was associated with SP (odds ratio (OR) = 2.23, 95%CI:1.35-17.40) <sup>[18]</sup> . However, Chen
	2	et al. reported that smoking was not associated with SP ( OR = 1.25, 95%CI: 0.99-1.35) <sup>[19]</sup> .
	3	In this study, we conducted a systematic review and meta-analysis to synthesize the
	4	prevalence of SP in different ages, sexes, and regions based on the general population and to
	5	evaluate the risk factors for SP.
	6	Materials and Methods
	7	Protocol registration
	8	This study was reported in accordance with the Preferred Reporting Items for Systematic
	9	reviews and Meta-Analyses (PRISMA) guidelines <sup>[20]</sup> and has been prospectively registered in
]	10	PROSPERO (registration number: CRD42019143295).
]	11	Search strategy
]	12	Nine databases were searched in this study, including Web of Science, PubMed, Embase,
]	13	Cochrane Library, CINAHL, CBM, CNKI, Wanfang, and VIP. The following strategy was used in
]	14	the searches: (Pruritus OR Itching) AND (Senile OR Aging OR Aged OR Geriatrics) AND
]	15	(Incidence OR Epidemiology OR Prevalence OR Risk factors). Complete details of the search
]	16	strategy are available in supplementary table S1. All of the databases were searched from
]	17	their inception dates to the 24 <sup>th</sup> of October 2020. Additional relevant literature was included
]	18	following a manual search of the included studies reference lists.
]	19	Inclusion and exclusion criteria
2	20	The inclusion criteria were as follows: (1) the study design was either cross-sectional study,
6 2	21	case-control study, cohort study or longitudinal study; (2) participants were greater than or

#### **BMJ** Open

equal to 60 years of age; (3) exact diagnostic criteria for SP were provided; (4) prevalence or risk factors for SP were reported. The exclusion criteria were as follows: (1) the study populations were inpatients and outpatients; (2) the prevalence or risk factor effect value (mainly referred to as OR in this study) of SP wasn't clearly reported in the original study, and the data provided by the original study couldn't calculate the prevalence or risk factor effect value of SP; (3) republished literature; (4) or studies published in a language other than Chinese or English. **Quality of the studies** Two independent reviewers assessed the quality of the included studies according to 11 criteria recommended by the American agency for healthcare research and quality (AHRQ). The criteria included assessment of selection bias, performance bias, attrition bias, detection bias, and publication bias. An item would be scored "1" if it was answered "YES", and if it was

answered 'NO' or 'UNCLEAR', then the item scored '0' <sup>[21]</sup>, providing a maximum score of 11.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### **Data extraction**

Study selection and data extraction were independently conducted by two reviewers. Any disagreement was resolved by discussion the two reviewers or a third reviewer. The articles were firstly screened by the title and abstract, and then full-text documents were reviewed for inclusion if they reported the prevalence and risk factors for SP. By using a standardized and pilot-tested form, two reviewers independently extracted data from eligible studies, including the title, first author name, publication year, study location, age, sample size, diagnostic criteria, prevalence and risk factors for SP.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### 1 Data analysis

2	Double arcsine transformation was used to convert the prevalence of SP so that the data can
3	follow an approximately normal distribution <sup>[22]</sup> . The ORs with their corresponding 95% CIs
4	were selected to assess the effect size of risk factors for SP. Heterogeneity among studies was
5	tested by Cochrane's $Q$ and $l^2$ statistics. Heterogeneity was recognized as significant when
6	$I^2$ >50%. A Fixed- effect model (Mantel and Haenszel method) was used if $I^2 \leq$ 50%, otherwise
7	a random-effects model (DerSimonian and Laird method) was used <sup>[23]</sup> . Forest plots were
8	constructed for a visual display of the pooled results if necessary. Four subgroup analyses
9	were conducted to explore the prevalence for SP in different age, sex, research sites and
10	region. Sensitivity analysis were assessed by excluding single studies. Publication bias was
11	assessed by using Begg's and Egger's tests <sup>[24]</sup> . Tests of Publication bias and sensitivity analysis
12	were not conducted in the risk factor analysis section due to the limited number of studies
13	included. Statistical analyses were conducted using STATA 15.1 (Stata Corp LP, College Station,
14	TX).
15	Results
16	Study Description
17	A total of 8,518 records were identified from the nine databases, of which 647 were duplicates.
18	After screening titles and abstracts, 7,740 records were excluded with reasons of age,
19	outcome, study design. Full-text documents of 131 records were screened, and 114 studies
20	were excluded with reasons listed as follows: participants were not $\geq$ 60 years of age (n= 49),
21	outcome was not senile pruritus (n= 44), not cross-sectional, case-control, cohort or

**BMJ** Open

1 longitudinal study (n= 9), non-Chinese and English study (n= 5), duplicate publication (n= 7).

2 In summary, 17 studies were eligible and included in the meta-analysis finally (Figure 1).

### 3 Characteristics of the included studies

4 The characteristics of the seventeen studies are summarized in Table 1. Eleven articles were

5 written in Chinese<sup>[18, 19, 25-33]</sup>, and six were written in English <sup>[34-39]</sup>. Thirteen studies were

6 conducted in Asia<sup>[18, 19, 25-33, 35, 37]</sup> and four in Europe <sup>[34, 36, 38, 39]</sup>. Sample sizes ranged from 45<sup>[39]</sup>

7 to 8,252<sup>[36]</sup>. Four of the seventeen studies reported the risk factors for SP<sup>[18, 19, 26, 33]</sup>.

#### 8 Table 1. Characteristics of included studies.

5	Authors	Publication	Study area	Diagnostic	Sample size	Prevalence(%)	Risk factors
0 7		Years		criteria			
8	Dalgard et al. <sup>[34]</sup>	2004	Norway	1	3876	6.91	NA
9 0	Li et al. <sup>[25]</sup>	2000	China	NA	534	12.36	NA
1	Xue et al. <sup>[27]</sup>	2008	China	NA	311	19.29	NA
3	Ni et al. <sup>[28]</sup>	2012	China	4	426	5.63	NA
4	Zhang et al. <sup>[29]</sup>	2012	China	NA	1283	9.90	NA
6	Li et al. <sup>[30]</sup>	2014	China	5	500	33.40	NA
7 8	Wu et al. <sup>[31]</sup>	2014	China	5	1286	42.38	NA
9	Yang et al. <sup>[32]</sup>	2014	China	NA	5000	33.84	NA
.0 .1	Tseng et al. <sup>[35]</sup>	2014	China	NA	313	7.35	NA
2	Miller et al. <sup>[36]</sup>	2016	Denmark	1	8252	6.31	NA
.3 .4	Kara et al. <sup>[37]</sup>	2017	Turkey	NA	105	19.05	NA
5	Cowdell et al. <sup>[38]</sup>	2017	Britain	6	1116	9.32	NA
.7	Dyhre et al. <sup>[39]</sup>	2019	Denmark	$\overline{O}$	45	28.89	NA
.8 .9	Ge et al. <sup>[26]</sup>	2006	China	2	1236	66.91	Age; xerosis; Astriction
0	Yang et al. <sup>[18]</sup>	2009	China	3	3785	61.98	Less water intake; Bathing with soap; Baths
1 2							too much; Smoking; Malignant tumor;
3	Chen et al. <sup>[19]</sup>	2015	China	4	200	10.50	Bathing with soap; Smoking; Chronic illness;
4							Excessive drinking; Monophagism;
5							Insomnia; Contact with animal
7	Hou et al. <sup>[33]</sup>	2016	China	4	398	18.09	Smoking; Chronic illness; Excessive drinking;
8							Monophagism; Insomnia; Contact with
9							animal
U I							

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Page 10 of 31

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ** Open

NA: not available. Diagnostic criteria: ① Self-reported skin complaints scale ; ② participants ≥60 years, an itch lasting more

than 2 weeks, Pruritus of whole body or multiple parts, no primary rash, no other pruritic skin disease, no obvious liver and kidney

damage, diabetes and mental disease. (3) Dermatology and Venereology; (4) Clinical Dermatology; (5) Dermatovenerolog; (6) Self-report skin diseases scale[38]; (7) Self-report skin diseases scale. **Risk of Bias Assessment** Results of the risk of bias assessment are listed in supplementary table S2. Higher scores indicative of less bias and more quality. Article quality was assessed as follows: 0 to 3 indicates a low quality, 4 to 7 indicates a moderate quality, and 8 to 11 indicates a high quality<sup>[40]</sup>. Study quality was found to be moderate in 11 studies and high in the other six studies. **Prevalence of SP** Seventeen studies, involving 28,666 participants reported the prevalence of SP, ranging from 5.63% to 66.91%. A random-effects model-based meta-analysis showed that the pooled prevalence of SP was 21.04% (95% Cl: 11.37%-32.72%). Subgroup analyses indicated that the pooled prevalence of SP for people aged 60-69, 70-79, 80-89, and ≥90 years old were 11.98% (95% CI :3.91%- 23.62%), 26.79% (95% CI: 8.71%- 50.36%), 51.31% (95% CI: 47.20%- 96.33%) and 57.53% (95% CI: 8.18%-n98.09%), respectively. The pooled prevalence of SP was 8.26% (95% CI: 5.88%-11.00%) in females and 18.65% (95% CI: 0.83%- 51.61%) in males. The pooled prevalence of SP in health examination centers, nursing homes and communities was 43.83% (95% Cl: 19.39%- 69.94%), 16.26% (95% Cl: (4.55%, 33.29%) and 12.21% (95% Cl: 3.46%-25.34%), respectively. The pooled prevalence of SP in Turkey and China was 24.34% (95% CI: 14.03%- 36.38%). The pooled prevalence of SP in Norway, Denmark and Britain was 8.23% (95% Cl: 6.36%- 10.35%). The results of subgroup analyses of age, sex, research site and region are

23 shown in Table 2.

Subgroup	Prevalence	95%CI (%)	Heterogene	eity
	(%)		<i>I</i> <sup>2</sup> (%)	P value
Age				
60-69	11.98	3.91-23.62	98.1	0.000
70-79	26.79	8.71-50.36	99.7	0.000
80-89	51.31	47.20-96.33	99.6	0.000
≥90	57.53	8.18-98.09	99.0	0.000
Sex				
Females	8.26	5.88-11.00	87.4	0.000
Males	18.65	0.83-51.61	99.9	0.000
Research sites				
Health examination center	43.83	19.39-69.94	99.8	0.000
Nursing homes	16.26	4.55-33.29	93.2	0.000
Community	12.21	3.46-25.34	99.8	0.000
Region				
Turkey, China	24.34%	14.03-36.38%	99.6%	0.000
Norway, Denmark, Britain	8.23%	6.36-10.35%	90.2%	0.000

Four studies, including 5,619 participants, reported the risk factors for SP [18, 19, 26, 33]. There were three studies<sup>[18, 19, 33]</sup>, including 4,383 participants, that reported the association of smoking and SP. Meta-analyses showed smoking was associated with SP [pooled OR of 1.26 (95% Cl: 1.14-1.40), I<sup>2</sup>=0%]. The results of two studies<sup>[19, 33]</sup>, involving 598 participants, suggested that excessive drinking increased the occurrence of SP [pooled OR of 25.03 (95% CI:18.28- 34.25), I<sup>2</sup>=0%]. Two studies<sup>[19, 33]</sup> involving 589 participants reported the association of Monophagism and SP [pooled OR of 1.22 (95% Cl: 1.12-1.33), I<sup>2</sup>=0%] (Table 3). 

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### Tab.3 Pooled risk factors of senile pruritus.

Ne	Diel: fe et e ve	08	05%/01	0	Heterogeneity	
NO.	RISK Idelors	UK	95%01	Ρ	l <sup>2</sup> (%)	P value
1	smoking	1.26	1.14 - 1.40	0.000	0%	0.673
2	excessive drinking	25.03	18.28 - 34.25	0.000	0%	0.980
3	monophagism	1.22	1.12 -1.33	0.000	0%	0.926

#### 3 Sensitivity Analysis

Sensitivity analysis was performed by excluding a single study and showed that the results of the meta-analysis were stable (18.61%- 22.23%). Sensitivity analysis was not conducted for the risk factor analysis due to the limited number of studies. **Publication Bias** Publication bias was assessed by using Begg's and Egger's tests. Begg's (Z=0.70, P=0.484) and Egger's test (t=0.26, P=0.796) results showed that the possibility of publication bias was less in the overall prevalence pooled analysis. Publication bias was not assessed in the risk factor analysis due to the limited number of studies. Discussion

In this study, 17 studies involving 28,666 participants were included encompassing Norway, China, Denmark, Turkey, and Britain. Subgroup analyses found that the difference in the prevalence of SP based on epidemiological factors. Subgroup analyses indicated that a steadily increasing prevalence of SP was associated with increasing age. Xerosis is related to aging and is reported as the most common cause of SP<sup>[41-43]</sup>. One of the skin's most important functions is to retain water. skin surface lipids and sebum on the skin helps retain water<sup>[44]</sup>. As skin ages,

#### **BMJ** Open

there is a decrease in lipids and sebum on the skin, leading to suboptimal moisture retention<sup>[42]</sup>. It was reported that pruritus can also be secondary to diabetes, kidney disease, liver disease, etc<sup>[44, 45]</sup>. Furthermore, pruritus is commonly listed as a medication complication<sup>[46]</sup>, including angiotensin-converting enzyme inhibitors, salicylates, chloro-quine, and calcium channel blockers<sup>[44]</sup>. However, elderly people have more basic diseases and complex medication, which also contributed to the higher incidence of pruritus. Another view is that SP is probably a subclinical neuropathy, degenerative change in peripheral nerve endings may be attributable to age. This age alteration can cause pruritus without specific stimuli<sup>[7]</sup>. In addition, immunosenescence occurs with aging and also produces a higher incidence of pruritus<sup>[42]</sup>. Moreover, decreases in androgen, estrogen and glucocorticoid in aged people can contribute to SP<sup>[47, 48]</sup>. All these factors will increase the prevalence of SP with age. The results of sub-regional analyses found that individuals who were living in Turkey and China were associated with a higher prevalence of SP. Pruritus is influenced by multiple factors, such as genetic, biological, psychological, social, environmental and cultural factors<sup>[49]</sup>. Different countries vary in society, culture, and environment, genetic, biological, and psychological factors also differ among populations in different countries. Therefore, the different prevalence among countries is related to the above factors. The results of sub-sex found that the prevalence of male is higher. Sub-research sites analyses found that the highest prevalence of SP was found in health examination centers. The reasons for these results are unclear based on the current scientific knowledge available on SP

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### **BMJ** Open

> prevalence. Further studies would be helpful in further exploring these phenomena. In conclusion, the prevalence of SP varies among different populations. However, the reasons underlying the differences in prevalence observed in the current study remain unclear. It is suggested that further studies of the prevalence of SP in different populations be conducted in the future.

Meta-analyses showed that smoking, excessive drinking, and monophagism were possible risk factors for SP. It has been shown that smoking can cause nutrient and oxygen deprivation in cutaneous tissues, decreases collagen and elastin fibers in the dermis, and increases keratinocyte dysplasia<sup>[50]</sup>. These changes reduce skin lipids, sebum, and moisture retention, leading to dryness and pruritus of skin<sup>[51, 52]</sup>. Therefore, smoking is a potential risk factor for SP. The present study also identified drinking alcohol as a potential risk factor for SP. Studies have demonstrated that alcohol consumption could reduce the concentration of carotenoids in the skin<sup>[53]</sup>. Carotenoids can neutralize free radicals, delay premature skin aging and skin diseases caused by free radicals<sup>[53-55]</sup>. It could be proposed that alcohol consumption may lead to skin diseases by affecting the concentration of carotenoids. The human body cannot synthesize carotenoids in sufficient amounts without relying on a nutrient rich diet including fruit and vegetables. Therefore, monophagism could contribute to reducing the concentration of carotenoids and it could be considered a risk factors for skin diseases. Regrettably, the specific types of monophagism wasn't pointed out in the included study, which prevented further analysis and discussion. We expect that follow-up studies will explore and investigate

#### **BMJ** Open

1	this. In addition, point out the participants' dietary structure and specific types of
2	monophagism.
3	Although the present study indicated smoking, excessive drinking and monophagism were
4	associated with an increased risk of SP, all the studies included in the meta-analysis were
5	cross-sectional. Consequently, It is not possible to infer on the causality between exposure
6	and outcomes. Further studies are needed to confirm these findings. In addition to the three
7	risk factors identified through the meta-analyses, the included studies also showed that the
8	risk factors for SP also include age, xerosis, astriction, less water intake, bathing with soap,
9	bathing too frequently, malignant tumor, chronic illness, excessive drinking, insomnia, and
10	contact with animals.
11	To the best of our knowledge, this study is the first to provide a systematic review of SP
12	prevalence and risk factors. However, several limitations of this study should be noted. First,
13	The epidemiological data on SP was only from Norway, China, Turkey, Britain, and Denmark,
14	which cannot be generalized to the worldwide population. Second, the methods of
15	identifying SP varied among the included studies, the definitions of SP may not be uniform
16	among investigators and researchers in different countries, the study of different countries
17	may not be unified in assessing the prevalence of SP, making it difficult to analyze the
18	prevalence of SP using a gold standard method. These limitations make we less confident that
19	the final estimate is close to a "true" estimate. Considering these limitations, further studies
20	will be needed to better understand the prevalence and risk factors of SP worldwide.
21	Conclusion

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

In conclusion, this study found the prevalence of SP was 21.04%. Individuals who were older,
 male, or living in Turkey and China were associated with a higher prevalence of SP.

- 3 Additionally, among health examination centers, nursing homes and communities, the highest
- $4 \qquad {\rm detection\ rate\ of\ SP\ was\ found\ in\ the\ health\ examination\ centers.\ Smoking,\ excessive\ drinking}$
- 5 and monophagism were possible individual risk factors for SP.

1			
2			
4		Refere	ences
5 6	1	1.	Valdes RR, Mollanazar NK, González MJ, et al. Itch Prevalence and
7	2		Characteristics in a Hispanic Geriatric Population: A Comprehensive Study Using
8	3		a Standardized Itch Questionnaire. Acta Derm Venereol. 2015:95(4):417-421.
9 10	4		doi:10.2340/00015555-1968
11	5		00.10.23+0/00013333 1900.
12	0	-	
13	0	Ζ.	Hosseinpoor AR, Bergen N, Chatterji S. Socio-demographic determinants of
14 15	7		caregiving in older adults of low- and middle-income countries. Age Ageing.
16	8		2013;42(3):330-338. doi:10.1093/ageing/afs196.
17	9		
18	10	3.	Darjani A, Mohtasham AZ, Mohammad AK, et al. Skin Disorders among Elder
19 20	11		Patients in a Referral Center in Northern Iran. Dermatol Res Pract.
20	12		2013;2013:193205. doi:10.1155/2013/193205.
22	13		
23	14	4.	Reszke R. Pełka D. Walasek A. et al. Skin disorders in elderly subjects. Int J
24 25	15		Dermatol 2015:54(9):332-338 doi: 10 1111/iid 12832
26	16		
27	17	E	Zhang Q. Wang HZ. Gao L et al. Effect of Traditional Chinese Medicine desire
28	10	5.	adjustment therapy on clean quality in national with scale chin provide Chin L
29 30	10		adjustment therapy on sleep quality in patients with senile skin pruntus. Chin J
31	19		Nurs. 2017;52(2):161-165. doi:10.3761/j.issn.0254-1769.2017.02.007.
32	20		
33 24	21	6.	Ständer S, Weisshaar E, Mettang T, et al. Clinical Classification of Itch: a Position
34 35	22		Paper of the International Forum for the Study of Itch. Acta Derm Venereol.
36	23		2007;87(4):291-4. doi:10.2340/00015555-0305.
37	24		
38	25	7.	Clerc CJ, Misery L. Venereologica, A Literature Review of Senile Pruritus: From
40	26		Diagnosis to Treatment. Acta Derm Venereol. 2017;97(4):433-440.
41	27		doi:10.2340/00015555-2574.
42	28		
43 44	29	8	Reich A. Ständer S. Szepietowski IC. Pruritus in the elderly. Clin Dermatol, Jan-
45	30	0.	Feb 2011:29(1):15-23, doi: 10.1016/i clindermatol 2010.07.002
46	21		100 2011,25(1).15 25. doi: 10.1010/j.cimacimatoi.2010.07.002.
47 40	20	0	Cabon KD. Frank I. Calhy DL, at al. Drugitus in the alderly Clinical approaches to
40 49	ა <u>2</u>	9.	Conen KK, Frank J, Salbu KL, et al. Pruntus in the elderly: Clinical approaches to
50	33		the improvement of quality of life. P&T. 2012;37(4): 227-239.
51	34		
52 52	35	10.	Zhang Q,Gao J,Shi LH, et al. Effect of Traditional Chinese Medicine desire
55 54	36		adjustment therapy on symptom and the quality of life in patients with senile
55	37		skin pruritu. Chin J Geront. 2016. 36(19): 4897-4899. doi:10.3969/j.issn.1005-
56	38		9202.2016.19.105.
57 58	39		
59			
60			

BMJ Open

3 4 5 6	1 2 3	11.	Teoh YL, Teo RY, Yeo B, et al. Elderly Hospitalised Patients-The Impact of Itch and its Prevalence. Ann Acad Med Singapore. 2016;45(4):134-137. PMID:27292003.
7	4		
8	5	12	Thainisuttikul V. Pruritic Skin Diseases in the Elderly. I Dermatol
9 10	6	12.	1008 ·25/2)·152 157 doi:10 1111/i 1246 8128 1008 tb02271 v
11	0		1598;25(5).155-157. 001.10.1111/J.1540-6158.1598.1002571.X.
12	(		
13	8	13.	Caretti KL, Mehregan DR, Mehregan DA. A survey of self-reported skin disease
14 15	9		in the elderly African-American population. Int J Dermatol. 2015;54(9):1034-8.
16	10		doi:10.1111/ijd.12520.
17	11		
18	12	14.	Rubegni P, Poggiali S, Nami N, et al. Skin diseases in geriatric patients: Our
19	13		experience from a public skin outpatient clinic in Siena 2012:147(6):631-636
20	14		
22	14		PMID.23149709
23	15		
24	16	15.	Liao YH, Chen KH, Tseng MP, et al. Pattern of Skin Diseases in a Geriatric Patient
25	17		Group in Taiwan: A 7-Year Survey from the Outpatient Clinic of a University
26 27	18		Medical Center. Dermat. 2001;203(4):308-313. doi:10.1159/000051778.
28	19		
29	20	16.	Reszke R, Pełka D, Walasek A, et al. Skin disorders in elderly subjects. Int J
30	21		Dermatol 2015:54(9):332-338 doi:10 1111/iid 12832
31	22		
32 33	22	17	Deselve D. Diskusiski Divula D. Lindney K. et al. Itak in Elderky Deseley A. Cross
34	23	17.	Reszke R, Białynicki-Birula R, Lindner K, et al. itch in Eiderly People: A Cross-
35	24		sectional Study. Acta Derm Venereol. 2019 ;99(11):1016-1021.
36	25		doi:10.2340/00015555-3271.
3/	26		
39	27	18.	Yang J, Zhao H, Zhou Y, et al. A case-control study on risk of 410 male senile
40	28		pruritus. Mod Prevent Med, 2009;36(10):1820-1822.
41	29		
42	30	19	Chen 7H Mo HX Xian IE et al. The study on the morbidity of common senile
43 44	21	15.	dermatesis in Juniing community in Guangzhou sity. J Jiaan Uniy, 2015;26(1);
45	20		
46	32		/3-/6. doi:10.11//8/j.jdxb.2015.01.013.
47	33		
48 40	34	20.	Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic
49 50	35		reviews and meta-analyses: the PRISMA statement. Syst Rev. 2015;4(1):1.doi:
51	36		10.1186/2046-4053-4-1.
52	37		
53	38	21	Zeng XT.Liu H.Chen X.et al. Meta analysis series 4: quality assessment tools for
54 55	30 20		observational studies Chin L Evid Rased Cardiovasc Med. 2012;4/04):207-200
56	35 40		
57	40		
58			
59 60			
00			

BMJ Open

2			
3	1	22.	Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-
4	2		analysis of binomial data. Arch Public Health. 2014 Nov 10:72(1):39. doi:
5	2		
0 7	J 4		10.1180/2049-5258-72-59.
8	4		
9	5	23.	Barili F, Parolari A, Kappetein PA, et al. Statistical Primer: heterogeneity,
10	6		random- or fixed-effects model analyses? Interact Cardiovasc Thorac Surg.
11	7		2018;27(3):317-321.doi: 10.1093/icvts/ivy163.
12 13	8		
14	0 0	24	Harrmann D. Sinnat D. Halmas I. at al. Statistical controversion in clinical
15	10	24.	
16	10		research: publication bias evaluations are not routinely conducted in clinical
17	11		oncology systematic reviews. Ann Oncol. 2017 May 1;28(5):931-937. doi:
18	12		10.1093/annonc/mdw691.
20	13		
21	14	25.	Li XS, He BX, Yang XQ. Investigation of dermatosis in cadres above division level
22	15		in Changchun, Shenyang Budui Viyao, 2000: 13(1):39
23	16		
24 25	10	•	
25 26	17	26.	Ge NL, Xie ZH, Zhang CL, et al. A case-control study on risk of 122 simple senile
27	18		pruritus. Chin J Epidemiol. 2006;27(7):627-629.
28	19		
29	20	27.	Xue SQ. Survey on Elderly Skin Disorders of Workers in Taigang Factory. Chin J
30	21		Dermatovenereol. 2008:22(7):409-410.
31 32	22		
33	22	20	Ni HI Ko XX Qian MQ, et al. Analysis of Provalence of Elderly Itch Skin Disease in
34	20	20.	
35	24		Two Pension Institutions in Shanghai. Chin J Dermato Venerol Integ Trad W
36	25		Med, 2012;11(3): 157-158.
37 38	26		
39	27	29.	Zhang L. The Dermatopathic Study Of Middle—age and elderly Cadres In
40	28		TaiYuan. Shanxi Medical University. Taiyuan, Shanxi, China, 2012.
41	29		
42	30	20	Li L Wang T Liu XZ. Analysis of rick factors and health guidance for senile
43 44	21	50.	Li L, Wang T, Liu X2. Analysis of tisk factors and fleating duance for senile
45	31		pruritus. J Milli Surg in Southwest Chin. 2014;(5):591-592.
46	32		doi:10.3969/j.issn.1672-7193.2014.05.050.
47	33		
48	34	31.	Wu N,Zhang DL. Investigation and etiological analysis of senile pruritus. Chin J
49 50	35		Convalescent Med. 2014;23(04):368-369. doi:10.13517/j.cnki.ccm.2014.04.051.
50	36		
52	37	37	Vang I. Dou N. Ma SH, et al. Influencing factors of senile pruritus in Tangshan
53	20	52.	city Chin L Coront 2014/24(19)/5205 5207 doi:10.2000/ilicer 1005
54	30		City. Chin J Geronit. 2014;34(18):5205-5207. doi:10.3969/J.ISSN.1005-
55 56	39		9202.2014.18.087.
57	40		
58			
59			
60			

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

3 1	1	33.	Hou XF, Zhang LJ. Investigation and analysis of 196 influencing factors of elderly
5	2		dermatosis. Shaanxi Med. 2016;45(11):1559-1560.
6	3		doi:10,11778/j.jdxb.2015.01.013.
7	4		
8	5	34	Dalgard F. Svensson A. Holm I. et al. Self-renorted skin morbidity in Oslo
9 10	6	54.	Associations with sociodomographic factors among adults in a cross socional
11	0		
12	(		study. Br J Dermatol. 2004 ;151(2):452-457. doi:10.1111/j.1365-
13	8		2133.2004.06058.x.
14 15	9		
16	10	35.	Tseng HW, Lam HC, Ger LP, et al. A survey of dermatological diseases among
17	11		older male adults of a Veterans Home in Southern Taiwan. Aging Clin Exp Res.
18	12		2015;27(2):227-33. doi:10.1007/s40520-014-0260-9.
19 20	13		
20	14	36	Miller IM, Zarchi K, Ellervik C, et al. Self-reported skin morbidity in Denmark: A
22	15	50.	nonulation based cross sectional study. Fur I Dermatel, 2016;26(2):281.6
23	10		
24 25	10		dol:10.1684/ejd.2016.2766.
25 26	17		
27	18	37.	Kara PA, Alatas ET, Doğan G, et al. Prevalence of Skin Diseases among Elderly
28	19		Residing in Nursing Homes in Mugla. TURK J GERIATR. 2017;20(1):23-29.
29	20		
30 31	21	38.	Cowdell F, Dyson J, Long J, et al. Self-reported skin concerns: An epidemiological
32	22		study of community-dwelling older people. Int J Older People Nurs.
33	23		2018·13(3)·12195. doi: 10.1111/opn
34	24		,,,,,,,,, _
35	21	20	Dubro DN Cazarani D. Brosonce and characteristics of capile pruvitus among
30 37	20	39.	Dynie PN, Gazerani P. Presence and characteristics of senile pruntus among
38	20		Danish elderly living in nursing nomes. Future Sci OA, 2019;5(6):Fs0399.
39	27		doi:10.2144/fsoa-2019-0036.
40	28		
41	29	40.	Xiong F, Lai YQ, Tu JX, et al. Epidemiological characteristics of sleep disorders in
43	30		the Chinese elderly: a meta-analysis. Chin J Evid-Based Med. 2020;19(4):398-
44	31		403. doi:10.7507/1672-2531.201808151.
45	32		
40 47	33	41.	Valdes RR, Stull C, Yosipovitch G. Chronic Pruritus in the Elderly:
48	34		Pathonhysiology Diagnosis and Management Drugs Aging 2015:32(3):201-15
49	35		doi:10.1007/s40266-015-0246-0
50	26		001.10.1007/340200-013-0240-0.
51	30 27	40	
53	31	42.	Pater 1, Yosipovitch G. The Management of Chronic Pruritus in the Elderly. Skin
54	38		Therapy Lett. 2010;15(8):5-9. 2010. PMID: 20844849.
55	39		
56 57	40	43.	Paul C, Maumus RS, Mazereeuw HJ, et al. Prevalence and Risk Factors for
58	41		Xerosis in the Elderly: A Cross-Sectional Epidemiological Study in Primary Care.
59	42		Dermatol. 2011;223(3):260-5. doi: 10.1159/000334631.
60			

BMJ Open

2			
3	1		
4 5	2	44.	Berger TG, Shive M, Harper GM. Pruritus in the older patient: a clinical review.
6	3		JAMA. 2013;310(22):2443-50. doi:10.1001/jama.2013.282023.
7	4		
8 9	5	45.	Ko MJ. Yang JY. Wu HY. et al. Narrowband ultraviolet B phototherapy for
10	6		patients with refractory uraemic pruritus: a randomized controlled trial. Br J
11	7		Dermatol 2011 Sep:165(3):633-9 doi: 10.1111/j.1365-2133.2011.10448 x
12 13	8		
14	9	46	Reich A. Ständer S. Szenietowski IC. Drug-induced pruritus: a review. Acta Derm.
15	10	40.	Vanaraal 2000:80/2):226 44 dai: 10.2240/00015555.0650
16 17	10	47	$\frac{1}{2}$
17	11	47.	Chin L Count 2010 20(10) 4500 4500 doi:10.2000 /i iour 4005
19	12		Chin J Geront. 2018,38(18),4598-4600. doi:10.3969/J.issn.1005-
20	13		9202.2018.18.087.
21	14		
23	15	48.	Liu YS. Endocrine system characteristics and diseases of the elderly. Chin J
24	16		Geriatr. 2005;24(8):637-639.
25	17		
26 27	18	49.	Tey HL, Yosipovitch G. Itch in ethnic populations. Acta Derm Venereol. 2010
28	19		May;90(3):227-34. doi: 10.2340/00015555-0867.
29	20		
30 21	21	50.	Leow YH, Maibach HI. Cigarette smoking, cutaneous vasculature, and tissue
32	22		oxygen. Clin Dermatol. 1998 Sep-Oct;16(5):579-84. doi: 10.1016/s0738-
33	23		081x(98)00042-x.
34	24		
35 36	25	51	Farage MA Miller KW Elsner P et al Intrinsic and extrinsic factors in skin
37	26	51.	ageing: a review. Int I Cosmet Sci. 2008 Apr: 30(2):87-95. doi: 10.1111/i.1/68-
38	$\frac{20}{97}$		2404 2007 00415 v
39 40	21		2494.2007.00413.X.
40 41	20	50	Friedman O. Changes and sisted with the aging free Fried Direct Cone Clip North
42	29	52.	Friedman O. Changes associated with the aging face. Facial Plast Surg Clin North
43	30		Am. 2005 Aug;13(3):371-80. doi: 10.1016/j.fsc.2005.04.004.
44 45	31		
46	32	53.	Lademann J, Meinke MC, Sterry W, et al. Carotenoids in human skin. Exp
47	33		Dermatol. 2011 May;20(5):377-82. doi: 10.1111/j.1600-0625.2010.01189.x.
48 40	34		Epub 2011 Mar 1.
49 50	35		
51	36	54	Berson DS. Natural antioxidants. J Drugs Dermatol. 2008 Jul;7(7 Suppl):s7-12.
52	37		
53 54	38	55.	Stahl W, Sies H. Bioactivity and protective effects of natural carotenoids.
55	39		Biochim Biophys Acta. 2005 May 30;1740(2):101-7.
56	40		doi:10.1016/j.bbadis.2004.12.006. Epub 2004 Dec 28.
57 59	41		
50 59	42		
60	10		

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

2	
ך ע	
6	
7	
2 2	
0	
9 10	
10	
11	
12	
13	
14	
16	
17	
18	
10	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1

#### Footnotes

#### 1 Author Statement

- 2 **Contributions:** Shi Chen and Fa-quan Zhou contributed equally to this study. Shi Chen
- 3 conceived and participated in the design of this review. Shi Chen and Fa-quan Zhou
- 4 performed the literature searches, study selection, data extraction, and assessed the risk of
- 5 bias. Shi Chen and Fa-quan Zhou drafted the manuscript. Yi-quan Xiong helped in performing
- 6 the analysis with constructive discussions. Shi Chen revised the final version. All authors read
- 7 and approved the final manuscript.
- 8 Funding: none
- 9 **Conflict of interests:** All of the authors declare that they have no financial or commercial
- 10 conflicts of interest.
- 11 Ethics approval: This article does not contain any studies with human participants or
- 12 animals performed by any of the authors.
- 13 **Patient consent for publication:** Not required.
- 14 **Patient and public involvement:** Patients and/or the public were not involved in the
- 15 design, conduct, reporting or dissemination plans of this research.
- 16 Data availability statement: All data relevant to the study are included in the article or
- 17 uploaded as supplementary information.
- 18 **Figure**
- 19 Fig. 1. Flowchart of the study selection process.
- 20 Supplementary
- 21 supplementary table S1. Complete search strategy.
- 22 supplementary table S2. Risk of bias assessment for the included studies.

#### Page 23 of 31

**BMJ** Open

Figure 1. Flowchart of the study selection process.



Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#### 

## Supplementary table S1.

Tab.S1 Risk of bias assessment for studies included.

Study	1	2	3	4	5	6	7	8	9	10	11	Total
												score
Li et al. <sup>[25]</sup>	Y	Ν	Y	Y	U	Y	Ν	Y	Ν	Ν	Ν	5
Dalgard et al. <sup>[34]</sup>	Y	Y	Y	Y	U	Y	Y	Y	Y	Y	Ν	8
Ge et al. <sup>[26]</sup>	Y	Y	Y	Y	U	Y	Y	Y	Ν	Y	Ν	8
Xue et al. [27]	Y	Ν	Ν	Y	U	Y	Y	Ν	Ν	Y	Ν	5
Yang et al. <sup>[18]</sup>	Y	Y	Y	Y	U	Y	Y	Y	Ν	Y	Ν	8
Ni et al. <sup>[28]</sup>	Y	Y	Y	Y	U	Y	Ν	Ν	Ν	Y	Ν	6
Zhang et al. <sup>[29]</sup>	Y	Y	Y	Y	U	Y	Ν	Ν	Ν	Y	Ν	6
Li et al. <sup>[30]</sup>	Y	Y	N	Y	U	Y	Ν	Ν	Ν	Y	Ν	5
Wu et al. <sup>[31]</sup>	Y	Y	Y	Y	U	Y	Ν	Ν	Ν	Y	Ν	6
Yang et al. <sup>[32]</sup>	Y	Y	Y	Y	U	Y	Y	Y	Ν	Y	Ν	8
Tseng et al. <sup>[35]</sup>	Y	Ν	Y	Y	U	Y	Y	Y	Ν	Y	Y	7
Chen et al. <sup>[19]</sup>	Y	Y	Y	Y	U	Y	Y	Ν	Ν	Y	Ν	7
Hou et al. <sup>[33]</sup>	Y	Y	Y	Y	U	Y	Y	Ν	Ν	Y	Ν	7
Miller et al. <sup>[36]</sup>	Y	Y	Y	Y	U	Y	Y	Y	Ν	Y	Ν	8
Kara et al. <sup>[37]</sup>	Y	Y	Y	Y	U	Y	Y	Ν	Ν	Y	Ν	7
Cowdell et al. <sup>[38]</sup>	Y	Y	Y	Y	U	Y	Y	Ν	Ν	Y	Ν	7
Dyhre et al. <sup>[39]</sup>	Y	Y	Y	Y	U	Y	Y	Ν	Y	Y	Ν	8

Y=YES; N= NO; U=Unclear; Score of Item (point): 1. Define the source of information (survey, record review); 2. List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications; 3. Indicate time period used for identifying patients; 4. Indicate whether or not subjects were consecutive if not population-based; 5. Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants; 6. Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements); 7. Explain any patient exclusions from analysis; 8. Describe how confounding was assessed and/or controlled; 9. If applicable, explain how missing data were handled in the analysis; 10. Summarize patient response rates and completeness of data collection; 11. Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained.

## Pubmed

- 1、 "Aged"[Mesh]
- 2、"Aging"[Mesh]
- 3、 "geriatrics"[Mesh]
- 4、 ((((((((((((((((((((((((((((())) Abstract]) OR aged[Title/Abstract]) OR senior

old[Title/Abstract]) OR geriatric[Title/Abstract]) OR elder[Title/Abstract]) OR old age[Title/Abstract]) OR pensioner[Title/Abstract]) OR veteran older adult\*[Title/Abstract]) OR older people[Title/Abstract]) OR older person\*[Title/Abstract]) OR older patient\*[Title/Abstract]) OR older women[Title/Abstract]) OR older men[Title/Abstract]) OR geriatrics[Title/Abstract]) OR senile[Title/Abstract]) OR senility[Title/Abstract]

- 5、#1 or #2 or #3 or #4
- 6、 "Pruritus"[Mesh]
- 7、 (((((((Pruritus[Title/Abstract]) OR Pruritis[Title/Abstract]) OR skin

pruritus[Title/Abstract]) OR Itching[Title/Abstract]) OR Skin disorders[Title/Abstract]) OR Dermatological problems[Title/Abstract]) OR skin diseases[Title/Abstract]) OR Senile Pruritus[Title/Abstract]) OR chronic pruritus[Title/Abstract]

- 8、#6 or #7
- 9、 "Incidence"[Mesh]
- 10、 "Prevalence"[Mesh]
- 11、 "Epidemiology"[Mesh]
- 12、 ((((((Epidemiology[Title/Abstract]) OR Prevalence[Title/Abstract]) OR

Incidence[Title/Abstract]) OR Incidences[Title/Abstract]) OR Incidence Studies[Title/Abstract]) OR Prevalences[Title/Abstract]) OR Prevalence Studies[Title/Abstract]) OR Epidemiologic Studies[Title/Abstract]

- 13、 #9 or #10 or #11 or #12
- 14、 "Risk Factors"[Mesh]
- 15、"Risk"[Mesh]
- 16、 "Root Cause Analysis"[Mesh]

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

#### 

17、 ((Risk Factors[Title/Abstract]) OR Risk[Title/Abstract]) OR Root Cause Analysis[Title/Abstract]

- 18、#14 or #15 or #16 or #17
- 19、#13 or #18
- 20、#5 AND #8 AND #19

#### Web of Science

1、TI=(aged or aging or older adult\* or older people or older person\* or older patient\* or older women or older men)

2. TI= (geriatric or geriatrics or elder\* or senile or senility or senior or old age or old or elder or pensioner or veteran).tw.

1 or 2

4、TS=(Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or

Dermatological problems or skin diseases or Senile Pruritus or f chronic pruritus)

5、TS=( Prevalence Prevalences or Prevalence Studies or Risk Factors or Root Cause

Analysis)

 $6\,,\quad$  3 and 4 and 5

#### Embase

- 1、exp Aged/
- 2、exp Aging/
- 3、 exp Geriatrics/

4. (aged or aging or older adult\* or older people or older person\* or older patient\* or older women or older men).tw.

5. (geriatric or geriatrics or elder\* or senile or senility or senior or old age or old or elder or pensioner or veteran).tw.

6、1 or 2 or 3 or 4 or 5



1	
2	
3	
4	7、 exp Pruritus/
5	
6	8 (Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or Dermatological
7	
8	problems or skin diseases or Senile Pruritus or f chronic pruritus) tw.
9	
10	9、7 or 8
17	
12	10 our Drouplance/
14	IO, exp Prevalence/
15	
16	11、 exp Risk Factor/
17	
18	12 exp Root Cause Analysis/
19	
20	
21	13、 ( Prevalence Prevalences or Prevalence Studies).tw.
22	
23	14 (Risk Factors or Root Cause Analysis) tw
24	
25	
20	15、10 or 11 or 12 or 13 or 14
28	
29	16、6 and 9 and 15
30	
31	
32	CINAHL
32 33	
32 33 34	CINAHL 1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")
32 33 34 35	CINAHL 1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")
32 33 34 35 36 37	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or</li> </ul>
32 33 34 35 36 37 38	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or</li> </ul>
32 33 34 35 36 37 38 39	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient*</li> </ul>
32 33 34 35 36 37 38 39 40	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient*</li> </ul>
32 33 34 35 36 37 38 39 40 41	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> </ul>
32 33 34 35 36 37 38 39 40 41 42	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4 (MH "Pruritus+")</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> <li>5、 AB Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> <li>5、 AB Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> <li>5、 AB Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or Dermatological problems or skin diseases or Senile Pruritus or chronic pruritus</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> <li>5、 AB Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or Dermatological problems or skin diseases or Senile Pruritus or chronic pruritus</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> <li>5、 AB Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or Dermatological problems or skin diseases or Senile Pruritus or chronic pruritus</li> <li>6、 S4 OR S5</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> <li>5、 AB Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or Dermatological problems or skin diseases or Senile Pruritus or chronic pruritus</li> <li>6、 S4 OR S5</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> <li>5、 AB Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or Dermatological problems or skin diseases or Senile Pruritus or chronic pruritus</li> <li>6、 S4 OR S5</li> <li>7、 (MH "Prevalence+") OR (MH "Risk Factors+") OR (MH "Root Cause Analysis+")</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> <li>5、 AB Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or Dermatological problems or skin diseases or Senile Pruritus or chronic pruritus</li> <li>6、 S4 OR S5</li> <li>7、 (MH "Prevalence+") OR (MH "Risk Factors+") OR (MH "Root Cause Analysis+")</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 52	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> <li>5、 AB Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or Dermatological problems or skin diseases or Senile Pruritus or chronic pruritus</li> <li>6、 S4 OR S5</li> <li>7、 (MH "Prevalence+") OR (MH "Risk Factors+") OR (MH "Root Cause Analysis+")</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 50	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> <li>5、 AB Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or Dermatological problems or skin diseases or Senile Pruritus or chronic pruritus</li> <li>6、 S4 OR S5</li> <li>7、 (MH "Prevalence+") OR (MH "Risk Factors+") OR (MH "Root Cause Analysis+")</li> <li>8、 AB Prevalence or Prevalences or Prevalence Studies or Risk Factor or Root Cause</li> </ul>
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	<ul> <li>CINAHL</li> <li>1、 (MH "Aged+") OR (MH "Aging+") OR (MH "geriatrics+")</li> <li>2、 AB aged or aging or geriatrics or senior or old or geriatric or elder or old age or pensioner or veteran or older adult* or older people or older person* or older patient* or older women or older men or senile or senility</li> <li>3、 S1 OR S2</li> <li>4、 (MH "Pruritus+")</li> <li>5、 AB Pruritus or Pruritis or skin pruritus or Itching or Skin disorders or Dermatological problems or skin diseases or Senile Pruritus or chronic pruritus</li> <li>6、 S4 OR S5</li> <li>7、 (MH "Prevalence+") OR (MH "Risk Factors+") OR (MH "Root Cause Analysis+")</li> <li>8、 AB Prevalence or Prevalences or Prevalence Studies or Risk Factor or Root Cause</li> </ul>

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23 ⊃4	
24	
25	
20	
27	
20	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
4/	
48	
49 50	
51	
57	
52 52	
52	
54	
56	
57	
58	
59	
60	

1

- 9、 S7 OR S8
- $10\space{-}$  S3 and S6 and S9

### **Cochrane Library**

- 1. MeSH descriptor: [Aged] in all MeSH products
- 2 MeSH descriptor: [Aging] explode all trees
- 3. MeSH descriptor: [Geriatrics] explode all trees
- 4 (Aging):ti,ab,kw OR (aged):ti,ab,kw OR (Geriatrics):ti,ab,kw OR (senior):ti,ab,kw OR (old):ti,ab,kw
- 5 (geriatric):ti,ab,kw OR (elder):ti,ab,kw OR (old age):ti,ab,kw OR (pensioner):ti,ab,kw OR (veteran):ti,ab,kw
- 6 (older adult\*):ti,ab,kw OR (older people):ti,ab,kw OR (older person\*):ti,ab,kw
   OR (older patient\*):ti,ab,kw OR (older women):ti,ab,kw
- 7、 (older men):ti,ab,kw OR (senile):ti,ab,kw OR (senility):ti,ab,kw
- 8、 #1 or #2 #3 or #4 or #5 or #6 or #7
- 9. MeSH descriptor: [Pruritus] explode all trees
- 10 (pruritus):ti,ab,kw OR (pruritis):ti,ab,kw OR (skin pruritus):ti,ab,kw OR (Itching):ti,ab,kw OR (Skin disorders):ti,ab,kw
- 11 (Dermatological problems):ti,ab,kw OR (skin diseases):ti,ab,kw OR (Senile Pruritus):ti,ab,kw OR (chronic pruritus):ti,ab,kw
- 12、 #9 or #10 or #11
- 13 MeSH descriptor: [Prevalence] explode all trees
- 14. MeSH descriptor: [Risk Factors] explode all trees
- 15. MeSH descriptor: [Root Cause Analysis] explode all trees
- 16、 (Prevalence):ti,ab,kw OR (Prevalences):ti,ab,kw
- 17 (Risk Factors):ti,ab,kw OR (Root Cause Analysis):ti,ab,kw
- 18、 #13 or #14 #15 or #16 or #17
- 19、 #8 and #12 and #18

#### CNKI

AB = ('老人'+ '老年'+ '老年人') AND AB = ('瘙痒性皮肤病'+ '瘙痒症'+'老年性皮肤瘙痒'+'老年性皮肤瘙痒症'+'搔痒'+'瘙痒') AND AB = ( '发病率'+ '发病率研究'+ '患病率'+ '现患调查' + '流行病学研究'+ '流行病学'+'风险关系' + '危险因素'+'危险' + '影响因素'+ '影响因素分析'+ '相关因素'+ '现况调查' + '相关性研究'+ '相关因素分析'+ '影响')

## Wanfang

(老年+老人+老年人) \* (瘙痒性皮肤病+瘙痒+瘙痒症+老年性皮肤瘙痒+老年 性皮肤瘙痒症+搔痒) \* (发病率+发病率研究+患病率+现患调查+流行病学研究 +流行病学+风险关系+危险因素+危险+影响因素+相关因素+现况调查+相关性研 究+相关因素分析+影响)

#### VIP

(U=老人 OR U=老年 OR U=老年人) AND (U=瘙痒性皮肤病 OR U=瘙痒 OR U=瘙痒 症 OR U=老年性皮肤瘙痒 OR U=老年性皮肤瘙痒症 OR U=搔痒) AND (U=发病率 OR U=发病率研究 OR U=患病率 OR U=现患调查 OR U=流行病学研究 OR U=流 行病学 OR U=风险关系 OR U=危险因素 OR U=危险 OR U=影响因素 OR U=影响 因素分析 OR U=相关因素 OR U=现况调查 OR U=相关性研究 OR U=相关因素分 析 OR U=影响)

#### CBM

1、"老年人"[不加权:扩展]

2、"老年人"[常用字段:智能] OR "老人"[常用字段:智能] OR "老年"[常用字段:智能] 3、(#1) OR (#2)

"瘙痒症"[不加权:扩展] 4、

7、"患病率"[不加权:扩展]

8、"横断面研究"[不加权:扩展]

9、"队列研究"[不加权:扩展]

"流行病学研究"[不加权:扩展]

"影响因素分析"[不加权:扩展]

用字段:智能] OR "相关因素分析"[常用字段:智能]

分析"[常用字段:智能] OR "相关因素"[常用字段:智能]

"流行病学"[不加权:扩展]

13、"危险因素"[不加权:扩展]

14、"危险"[不加权:扩展]

5、"瘙痒性皮肤病"[摘要:智能] OR "瘙痒"[摘要:智能] OR "瘙痒症"[摘要:智能] OR

要:智能]

10、

11、

12、

15、

17、(#7-16)

18、(#3) AND (#6) AND (#17)

6、(#4) OR (#5)

 "老年性皮肤瘙痒"[摘要:智能] OR "老年性皮肤瘙痒症"[摘要:智能] OR "搔痒"[摘

"发病率"[常用字段:智能] OR "发病率研究"[常用字段:智能] OR "患病率"[常用

字段:智能] OR "现患调查"[常用字段:智能] OR "流行病学研究"[常用字段:智能] OR

"流行病学"[常用字段:智能] OR "现况调查"[常用字段:智能] OR "相关性研究"[常

16、"影响"[常用字段:智能] OR "风险关系"[常用字段:智能] OR "危险因素"[常用字

段:智能] OR "危险"[常用字段:智能] OR "影响因素"[常用字段:智能] OR "影响因素

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ge 31 of 31		BMJ Open	
PRISMA 2	:009	Checklist opyright -2021-	
Section/topic	#	Checklist item	Reported on page #
TITLE		g fo	
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT		as reiginary	
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitation; study appraisal appraisal appraisal approximation; study appraisal approximation; study appraisal approximation; study appraisal approximation; study approximation;	1-2
		xt ar ar	
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants for eventions, comparisons, outcomes, and study design (PICOS).	3-4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristic الله (e.ﷺ, years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
nformation sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic www, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in deplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including nearly asures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	6



## PRISMA 2009 Checklist

		BMJ Open Greet B	Page 32 of
PRISMA 20	009	Checklist	
		Page 1 of 2	
Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-real significant indicating which were pre-specified.	6
RESULTS		d to	
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, where asons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, Provide the citations.	7-8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessme the term 12).	8
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple surged data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot	9-11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measured of consistency.	9-11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	11
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-	11
DISCUSSION	<u> </u>	je na se	
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	11-13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., ineomplete retrieval of identified research, reporting bias).	13-14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19
)   <i>From:</i> Moher D, Liberati A, Tetzlaf 2 doi:10.1371/journal.pmed1000097 3	ff J, Altm	an DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The BRISMA Statement. PLoS Med For more information, visit: www.prisma-statement.org. Page 2 of 2 For peer review only - http://bmiopen.bmi.com/site/about/guidelines.xhtml	6(6): e1000097.